The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis

被引:0
|
作者
Engel, LS
Callegan, MC
Hill, JM
Folkens, AT
Shimomura, Y
OCallaghan, RJ
机构
[1] LOUISIANA STATE UNIV,CTR EYE,NEW ORLEANS,LA 70112
[2] LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT MICROBIOL IMMUNOL & PARASITOL,NEW ORLEANS,LA 70112
[3] ALCON LABS INC,FT WORTH,TX 76101
[4] OSAKA UNIV,SCH MED,DEPT OPHTHALMOL,SUITA,OSAKA 565,JAPAN
关键词
Ciloxan(R); ciprofloxacin-PSS; keratitis Pseudomonas; rabbits; Staphylococcus;
D O I
暂无
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Ciprofloxacin is a fluoroquinolone antibiotic with broad spectrum bactericidal activity. A commercially available form of ciprofloxacin contains benzalkonium chloride (BAC) (0.006%) and EDTA (0.05%) as preservatives. Since BAG has been shown to cause adverse changes in corneal epithelial cells, a formulation of ciprofloxacin devoid of BAC and EDTA but with the same effectiveness would be valuable. We present here the results of experiments designed to assess the efficacy of a BAC-free and EDTA-free formulation of ciprofloxacin, Ciprofloxacin-polystyrene sulfonate (PSS), in experimental models of Pseudomonas aeruginosa and Staphylococcus aureas keratitis, Both formulations of ciprofloxacin sterilized corneas infected with P aeruginosa, and both formulations showed equal bactericidal activity for S aureus, Normal eyes treated with either formulation showed mild conjunctival irritation compared to untreated normal eyes. The bactericidal activities of both formulations of ciprofloxacin were excellent, Therefore, the Ciprofloxacin-PSS formulation could serve as an effective single drug therapy for ocular infections.
引用
收藏
页码:212 / 219
页数:8
相关论文
共 50 条
  • [31] ENOXACIN THERAPY FOR EXPERIMENTAL PSEUDOMONAS KERATITIS
    ESPOSITO, S
    THADEPALLI, H
    BENLER, HA
    CHUAH, SK
    JOURNAL OF CHEMOTHERAPY, 1991, 3 (03) : 147 - 151
  • [32] TICARCILLIN IN TREATMENT OF EXPERIMENTAL PSEUDOMONAS KERATITIS
    AHMAD, A
    SMOLIN, G
    OKUMOTO, M
    OHNO, S
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1977, 61 (02) : 92 - 95
  • [33] NEBCIN IN TREATMENT OF EXPERIMENTAL PSEUDOMONAS KERATITIS
    BELFORT, R
    SMOLIN, G
    OKUMOTO, M
    KIM, HB
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1975, 59 (12) : 725 - 729
  • [34] Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis
    McCormick, Clare
    Caballero, Armando
    Tang, Aihua
    Balzli, Charles
    Song, Jenny
    O'Callaghan, Richard
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (06) : 1569 - 1575
  • [35] EFFECTIVENESS OF SPECIFIC ANTIBIOTIC STEROID COMBINATIONS FOR THERAPY OF EXPERIMENTAL PSEUDOMONAS-AERUGINOSA KERATITIS
    ENGEL, LS
    CALLEGAN, MC
    HOBDEN, JA
    REIDY, JJ
    HILL, JM
    OCALLAGHAN, RJ
    CURRENT EYE RESEARCH, 1995, 14 (03) : 229 - 234
  • [36] Bioequivalence of two oral ciprofloxacin tablets formulations
    Cuadrado, A
    Gascón, AR
    Solinís, MA
    Ramirez, E
    Hernández, RM
    Knie, U
    Pedraz, JL
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2004, 42 (06) : 336 - 341
  • [37] Understanding clinical and immunological features associated with Pseudomonas and Staphylococcus keratitis
    Shrestha, Gauri Shankar
    Vijay, Ajay Kumar
    Stapleton, Fiona
    Henriquez, Fiona L.
    Carnt, Nicole
    CONTACT LENS & ANTERIOR EYE, 2021, 44 (01): : 3 - 13
  • [38] Comparative bioavailability of two oral formulations of ciprofloxacin
    Trejo, D
    Toledo, A
    Carrasco-Portugal, MD
    Aguilar-Cota, ME
    Herrera, JE
    Flores-Murrieta, FJ
    PROCEEDING OF THE FORTY-SIXTH ANNUAL MEETING OF THE WESTERN PHARMACOLOGY SOCIETY, 2003, 46 : 134 - 135
  • [39] DIFFERENCES IN EFFECTIVENESS OF SPECIFIC ANTIBIOTIC STEROID COMBINATIONS FOR THE THERAPY OF EXPERIMENTAL PSEUDOMONAS-AERUGINOSA KERATITIS
    ENGEL, LS
    CALLEGAN, MC
    HOBDEN, JA
    HILL, JM
    OCALLAGHAN, RJ
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1994, 35 (04) : 1339 - 1339
  • [40] The effectiveness of tobramycin and Ocuflox® in a prophylaxis model of Staphylococcus keratitis
    Dajcs, JJ
    Moreau, JM
    Stroman, DW
    Schlech, BA
    Ke, TL
    Thibodeaux, BA
    Girgis, DO
    Caballero, AR
    O'Callaghan, RJ
    CURRENT EYE RESEARCH, 2001, 23 (01) : 60 - 63